ISRG (Intuitive Surgical) NASDAQ pre-market $485.84 16 Feb 2026: AI edge in surgeries

ISRG stock opened pre-market at $485.84 on 16 Feb 2026 on the NASDAQ in the United States, reflecting a 1.51% intraday gain as investors react to recent quarter results and AI-driven product positioning. We see durable revenue expansion and strong cash flow but a premium valuation with a PE of 61.89 and a market cap of $172.54 billion USD. For AI stocks strategy readers, Intuitive Surgical’s integration of data and imaging into its da Vinci and Ion platforms is the key driver we will track into the next earnings cycle.

ISRG stock: Pre-market snapshot and intraday drivers

ISRG stock trades at $485.84 with a day range $479.61–$495.57 and volume at 1,984,623 shares versus an average volume of 1,910,578. The 50-day average is $543.92 and the 200-day average is $516.12, showing recent price weakness despite year-over-year growth in procedures.

Earnings and near-term revenue momentum

Intuitive Surgical reported $2.53 EPS and $2.87 billion revenue for the last quarter, beating consensus and growing revenue 18.8% year-over-year. Analysts expect 6.43 EPS for the fiscal year; the next official earnings date is 21 Apr 2026, which will test whether procedure adoption and consumable sales continue to accelerate.

ISRG stock valuation and financials

The company shows strong margins with a net margin 28.38%, EPS 7.85, and free cash flow per share 7.02. Valuation remains rich: price-to-sales 17.13, price-to-book 9.67, and trailing PE near 61.89, leaving limited margin for disappointment given the current multiples.

ISRG stock technicals and trading signals

Momentum indicators show an RSI of 65.69 and MACD slightly positive, suggesting bullish bias but nearing overbought conditions. Technical support sits near the 200-day average $516.12; short-term resistance cluster spans $542.28–$566.22 on Bollinger mid and lower bands.

Meyka AI rates ISRG with a score out of 100

Meyka AI rates ISRG with a score of 79.59 out of 100 — Grade: B+, Suggestion: BUY. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. The rating balances strong cash flows, 3-year revenue growth, and institutional ownership against a high PE and elevated price-to-sales ratio. These grades are not guaranteed and we are not financial advisors.

Risks, sector context, and AI opportunities

Key risks include valuation sensitivity, slower procedure uptake, and rising competition in robotic-assisted and diagnostic platforms. The Healthcare sector shows defensive characteristics but AI-enabled imaging and software could expand addressable markets for Intuitive. We view product-driven AI features as the most relevant opportunity for long-term procedure and consumable growth.

Final Thoughts

Key takeaways for ISRG stock: Intuitive Surgical shows durable demand and strong margins but trades at a premium that leaves little room for execution slips. Meyka AI’s forecast model projects a yearly target of $604.32, implying an upside of 24.39% versus the current price of $485.84 USD; forecasts are model-based projections and not guarantees. Our view frames ISRG as an AI-era healthcare growth name with balanced risk from valuation and insider selling activity. We will watch April 21, 2026 earnings and adoption metrics for Ion and da Vinci software upgrades to confirm the growth thesis. For a deeper data view, see our Meyka AI stock page on ISRG and the latest market commentary from news sources below.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.